Milestone reports Q3 net loss $11.9M; PDUFA target Dec 13 for CARDAMYST in PSVT

Milestone Pharmaceuticals Inc.

2025-Q3 EPS reported -$0.60 vs consensus -$0.17 ▼ miss (-258.6%)

Cash, equivalents and short-term investments $82.6M at Sept 30, up from $69.7M at Dec 31, 2024.
Net loss Q3 $11.9M vs $9.4M a year ago; no revenue reported in either period.
Commercial expense surged to $4.6M (Q3) from $1.9M on launch prep for potential FDA approval.
NDA for CARDAMYST (etripamil) under FDA review; PDUFA action date December 13, 2025.
Completed $48.7M equity offering and amended Royalty Purchase Agreement securing $75M upon approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.